By Darcy Grabenstein
è£œè¬æ¥çã«ã©ããªæªæ¥ãåŸ ã£ãŠããã®ããæ°Žæ¶çãèŠã蟌ãå£ç¯ããã£ãŠããã2025幎ã¯äºæ³å€ã®ããããŠããããããåäŸã®ãªãå±éãåŸ ã¡åããŠãããããããªããã·ãŒããã«ããç· ããã¯ã€ã«ããªæ ã«åãããã
AI
ã©ã€ããµã€ãšã³ã¹æ¥çïŒãããã¯ã©ã®æ¥çãåãã ãïŒã«ããã人工ç¥èœã®è©±é¡ã¯èã飜ãããããããªãããç§ãã¡ã¯ããã«æ £ããªããã°ãªããªãã ããããã®è©±é¡ãããã«ãªããªãããšã¯ãªãã ããã
AIãåãå·»ã話é¡ã¯å€ãããæ¥çã®å°éå®¶ã¯ã¬ãŒãã¬ãŒã«ã®å¿ èŠæ§ã匷調ããŠãããCiteline瀟ã®ã¯ãªãã«ã«ã»ãœãªã¥ãŒã·ã§ã³æ åœå¯ç€Ÿé·ã§ããã¯ã¬ã¢ã»ãªããã§ã¹æ°ã¯ãä»å¹Žåãã«éå¬ãããCiteline Elevateã€ãã³ãã§ãèšåºç ç©¶ã«ãããAIã®å¿çšã«äŒŽããªã¹ã¯ã¯ãéšå±ã®äžã®è±¡ãã§ãããšææãããããããæãããŸããã£ãŠããäŒæ¥ã¯ãèšåºSMEãšããŒã¿ãšAIãçµã¿åããããã®ãªã¹ã¯ãåã£ãŠããäŒæ¥ã§ããããšãªããã¹æ°ã¯Nordic Life Science Daysã®ããã«ãã£ã¹ã«ãã·ã§ã³ã§è¿°ã¹ãã
ã·ãã£ã©ã€ã³ã®ã¯ãªãã«ã«ã»ã¢ããªãã£ã¯ã¹æ åœãã£ã¬ã¯ã¿ãŒã§ããã«ã«ã»ããªã·ã¯ãè£œè¬æ¥çã§ã¯AIã®æ¬¡ã®æ®µéããã§ã«å§ãŸã£ãŠãããšèšãã圌ã¯ããã€ãã®äŸãæããŠããïŒ
- AIã¯ãåå¥åå»çã匷åããããã®ãããžã¿ã«ã»ãã€ã³ããéçºããããã«æ¡çšããããšãã§ããã
- GenAIãã©ãããã©ãŒã ã¯ååèšèšãæé©åããããšã§åµè¬ãå éããã
- EdgeAIã¯ããŠã§ã¢ã©ãã«ããã€ã¹ã®äœ¿çšã«ããæ£è ã®é éã¢ãã¿ãªã³ã°ã§ããã忣åãããèšåºè©Šéšãæ¯æŽããã
- éåæ©æ¢°åŠç¿ïŒMLïŒã¯ãä»£æ¿æ²»ççµè·¯ãšãã®çµæãäºæž¬ããããšãã§ããã
- éåAIã¯ãå®äžçããŒã¿ïŒRWDïŒãé»åã«ã«ãïŒEHRïŒãªã©ã®è¢«éšè ã¬ãã«ã®ããŒã¿ã®æå·åã匷åããããšãã§ããã
èšåºè©Šéšã®å€æ§æ§
ç±³åœã®èšåºè©Šéšã«ããã倿§æ§ã®åé¡ã¯ã1986幎ã«ç±³åœåœç«è¡çç ç©¶æããèšåºç ç©¶ã«ããã女æ§ãšãã€ããªãã£ã®å æïŒInclusion of Women and Minorities in Clinical ResearchïŒããšããæ¹éãæ¡æããããšã§ã¯ããŒãºã¢ãããããã
ããã«æè¿ãFDAã¯ãèšåºè©Šéšã«ãããäžç¹å®å€æ°ã®åå è ã®ç»é²ãæ¹åããããã«ã倿§æ§è¡åèšç»ïŒDAPïŒã«é¢ããã¬ã€ãã³ã¹ææžãèµ·èãããFDAã¯2025幎6æïŒã¬ã€ãã³ã¹èæ¡ã«å¯Ÿããã³ã¡ã³ãæéçµäºãã9ã¶æåŸïŒãŸã§ã«æçµçãªDAPã¬ã€ãã³ã¹ãçºè¡ããããšã矩åä»ããããŠããã
ã¬ã€ãã³ã¹ã§ã¯ã第⠢çžèšåºè©ŠéšãŸãã¯ãã®ä»ã®æ¥µããŠéèŠãªèšåºè©Šéšã«é¢ãã以äžã®èŠä»¶ãæŠèª¬ãããŠãããããåã«ããããšè¯ãããã®ã§ãã£ããã®ããä»åŸã¯å¿ é ãšãªãïŒ
- èšåºè©Šéšç»é²ã«é¢ããã¹ãã³ãµãŒã®æ ¹æ ãšç®æšãæèšããïŒèšåºçã«é¢é£ãã詊éšéå£ã®å¹Žéœ¢å±€ãæ°ææ§ãæ§å¥ã人皮ã§åããïŒ
- ã¹ãã³ãµãŒããããã®ç®æšãã©ã®ããã«éæããã€ãããã説æããã
ãŸããLGBTQIA+ãåŠåš äžã®å¥³æ§ãé«éœ¢è ãªã©ãèšåºè©Šéšã«ãããŠç€ŸäŒããçå€ãããã°ã«ãŒããžã®æ³šç®ãé«ãŸãããšãäºæ³ãããã
ç±³åœã®æ°æ¿æš©
ããã«ãã»ãã©ã³ãæ°ã次æç±³åœå€§çµ±é ã«éžåºãããè£œè¬æ¥çå šäœã«è¡æãèµ°ã£ããæ¥çé¢ä¿è ã¯éžæçµæã«ãã¡æ©ãåå¿ããæ°æ¿æš©ãã©ã€ããµã€ãšã³ã¹ã«åãŒãå¯èœæ§ã®ãã圱é¿ã«ã€ããŠæèŠãè¿°ã¹ããç±³åœç 究補è¬å·¥æ¥åäŒïŒPhRMAïŒã®ã¹ãã£ãŒãã³ã»ãŠãã«äŒé·å Œæé«çµå¶è²¬ä»»è ïŒCEOïŒã¯å£°æã®äžã§ããããããã¯ããã©ã³ãæ¿æš©ããã³æ°è°äŒãšååããŠãå»çå¶åºŠãæ£è ã«ãšã£ãŠããè¯ããã®ã«ããããã«å°œåããããšè¿°ã¹ãã
ãã©ã³ã倧統é ãFDAé·å®ã«éžãã ã®ã¯ãå»åŠçã®æ¢ææŠå¿µã«ææŠããããšã§ç¥ãããããŒãã£ã»ãã«ãªãŒã§ããããã«ãªãŒã¯ãšããã³ã¹ã«åºã¥ãå»çãžã®æ¯æã衚æããäžæ¹ã§ãèªèº«ã®ç«å Žãåé²ãããããã«ããŒã¿ãè¿åããããã誀ã£ãŠè§£éããããšãããããã圌ã®ä»»åœã¯æ éãªæ¥œèгè«ã§åãæ¢ããããŠããããã®ããã圌ã®å°±ä»»ã¯æ éãªæ¥œèгè«ã§åãæ¢ããããŠããã
ç±³é£åå»è¬åå±ïŒFDAïŒã®çç©è£œå€è©äŸ¡ç ç©¶ã»ã³ã¿ãŒïŒCBERïŒã®ããŒã¿ãŒã»ããŒã¯ã¹æé·ã¯ããã©ã³ãæ¿æš©ã«ãã£ãŠFDAã®å°éæ§ãè ãããããšã¯èããŠããªããšCitelineã®Scripã«èªã£ãã
ãã©ã³ã倧統é ãä¿å¥çŠç¥ïŒHHSïŒé·å®ã«éžãã ã®ã¯ãã¯ã¯ãã³å察ã§ç¥ããããããŒãã»Fã»ã±ããã£ã»ãžã¥ãã¢ã ãã¹ã³ããã»ãŽãããªãŒãåFDAé·å®ãšãããŒãã»ã«ãªãçŸFDAé·å®ã¯ãFDAã®å°æ¥ã«ã€ããŠè¿·ã£ãŠããã
æ¥çã«ãšã£ãŠæããææãšããŠã¯ããã©ã³ã倧統é ãæ°æ¿åºå¹ççã®å ±å責任è ã«éžãã ãããã¯ã»ã©ãã¹ã¯ãæ°ããå»è¬åã®å¯©æ»ãããå³ãããããããæ©ãæ¿èªããããšãæå±ããŠããã
å ±åå äž»å°ã®æ¿æš©ãèªçããBIOSECUREæ³ã®æç«ãè¿ã¥ããããããªãããã®æ³åŸã¯ãé£éŠæ¿åºããè³éæŽå©ãåããŠããäŒæ¥ããäžåœãªã©å€åœã®æµå¯Ÿå¢åãšé¢ä¿ã®ããäŒæ¥ã®ãã€ãªãã¯ãããžãŒã䜿çšããããšãçŠæ¢ãããã®ã§ãããããã³ã¯ã·ãŒãç·šéé·ã®ããŒã«ã»ã³ã»ãããã¹ã¯ãããã©ã³ãåå©ã¯ããã€ãªè£œè¬æ¥çã«ãšã£ãŠå€ãã®é¢ã§äžç¢ºå®æ§ããããããè£œè¬æ¥çã¯äžåœåžå Žã«åŒãç¶ãã³ãããããŠãããBIOSECUREãééããŠããããç¶ããã ããã"
ãã©ã³ãã¯å€§çµ±é 就任1æç®ã«ãç±³åœãäžçä¿å¥æ©é¢ïŒWHOïŒããè±éãããããã€ãã³ã¯ååœã®å çã埩掻ããããããã©ã³ãããã®åœä»€ãåãæ¶ãããšããŠãäžæè°ã§ã¯ãªãã
èšåºè©Šéšã®é瀺
å»è¬åæ å ±åäŒ(DIA)ã®äŒå¡ã«ããã°ãçŸåšã欧å·ãæ å ±é瀺ãçœåŒããŠãããã·ãã£ãŒã©ã€ã³ç€Ÿã®ã°ããŒãã«éææ§æ åœå¯ç€Ÿé·ãã©ã³ã·ãŒãã»ã¬ã€ã³æ°ã¯ãä»åŸã欧å·ãæ å ±é瀺ãçœåŒããŠãããšäºæž¬ããŠãããCTISãžã®å®å šç§»è¡ãïŒå°ãªããšãå ¬åŒã«ã¯ïŒ1ææ«ãŸã§ã«å®äºããããšãããæ¬§å·ã¯æ¥å¹Žãæ å ±é瀺ã®äž»å°æš©ãæ¡ãç¶ããã ããã
欧å·å»è¬ååºæ¹é0070ã®ç¬¬2段éã¯2025幎4æã«æœè¡ããããã¬ãŒã³æ°ã¯ãPolicy 0070ãšè£œåæ¿èªæã«èšåºè©Šéšå ±åæžïŒCSRïŒã®æåºãæ±ããèšåºè©ŠéšèŠå¶ïŒCTRïŒã«é¢ãããããªãã¬ã€ãã³ã¹ãæ¢ãããè¿°ã¹ãŠããã
ããã«ãè±åœã¯10æã«ã2026幎ã«çºå¹ãäºå®ãããŠããåŸ æã®ãã¬ã°ãžããåŸã®èšåºè©ŠéšèŠå¶ãä»å¹Žäžã«æçµæ±ºå®ãããšçºè¡šããã
ã·ãã£ã©ã€ã³ã®ããŒãã¹ã»ãŠã£ãã¯ã¹ã¯ã2025å¹Žã®æ å ±é瀺ã«é¢é£ãããã¬ã³ãã®æ°ã ãäºæž¬ããŠããïŒ
- EUãšè±åœãå å°ããããå€ãã®åœã远éããå¹³æãªèŠçŽïŒPLSïŒãžã®éèŠã®é«ãŸã
- GDPRãšä»åŸäºå®ãããŠããæ¬§å·å»çããŒã¿ã¹ããŒã¹ïŒEHDSïŒã®èŠä»¶ã«æºæ ãããããããŒã¿ã®å¿ååãšåç·šéãããæŽç·Žãããæ¹æ³ã§è¡ãã
- é©å¿çãã¢ãŠãã«ã ææšã驿 Œæ§åºæºã«é¢ããããè¯ãããŒã¿æ§é åãå«ããã³ã³ãã©ã€ã¢ã³ã¹ããé瀺ãããæ å ±ã®è³ªãšäžè²«æ§ãžã®çŠç¹ã®ã·ããã
- AIã®ãã¬ã³ãã¯æ å ±é瀺ã«ãåãã§ãããPLSã詊éšçµæã®ãµããªãŒãããåç·šéãå ±åæžäœæã«ãŸã§åãã§ããã
APACãèŠã
ç±³åœã𿬧å·ã ãã§ãªããAPACã®å°éå®¶ãæ¥çã«æåŸ ãããããšãæŠèгããã2025幎ã«ãããæãã€ã³ãã¯ãã®ããã©ã€ããµã€ãšã³ã¹ã®ãã¬ã³ãã¯ããã®å°åãäžçã®èå°ã§å é²çèšåºè©Šéšã®ãªãŒããŒãšããŠåžžæ åããããšã§ãããããšã·ãã£ãŒã©ã€ã³ã®APACã³ã³ãã³ãæ åœãã£ã¬ã¯ã¿ãŒãã¢ããŒã»ã·ãŠã¯èšãã
äžåœã§ã¯ãã·ãã¢ã»ãšãã£ã¿ãŒã®ãã¯ã¹ã¿ãŒã»ã€ã³ãšã·ãã¢ã»ã¬ããŒã¿ãŒã®ã·ã¥ãŒã»ããŒã¯ãäžåœã®å»è¬åã¡ãŒã«ãŒã¯ãçŸåšã®ããã¡ã¹ãã»ãã©ãã¯ãŒãç ç©¶éçºæŠç¥ã«å ãããã¡ãŒã¹ãã»ã€ã³ã»ã¯ã©ã¹ã®æ²»çæ³ãå«ãç¬èªã®ã€ãããŒã·ã§ã³ããŸããŸã远æ±ããããã«ãªããšææããŠãããæšå¹Žãäžåœåœå ã®4ã€ã®èªç±è²¿æåºã«ãããŠãçŽ°èæ²»çãšéºäŒåæ²»çã®åéãå€è³ã®çŽæ¥æè³ã«éæŸããããããã«ãå€è³ç³»å€§æè£œè¬äŒç€Ÿã¯äžåœã§ã®é©æ°çãªå»è¬åéçºãæ¡å€§ãããšäºæ³ããããæåŸã«ããã€ãªãã³ãã£ãŒã®è³é調éé£ãç¶ãäžãäžåœã®ãã€ãªãã³ãã£ãŒãšå€§æè£œè¬äŒç€Ÿãå·»ã蟌ãã M&A掻åãæŽ»çºåããå¯èœæ§ãããã
ã·ãã£ã©ã€ã³ã®é«æšãªãµç·šéé·ãšã€ã¢ã³ã»ãã€ããã¯ç·šéé·ã«ãããšããã©ã³ã倧統é ã®èªçã¯æ¥æ¬ã«ãæ³¢åããæ¥æ¬ã®è£œè¬äŒç€Ÿã®ç±³åœã§ã®å€§ããªå£²äžã«åœ±é¿ãäžããå¯èœæ§ããããšãããæ¥æ¬ã¯ãŸããæè¿ã®åœæ¿éžæã§åŒ±äœåããèªæ°å ããããæ¿æ²»çã»æ¿ççäžç¢ºå®æ§ã«ãçŽé¢ããŠããã圌ãã¯ãä»ã®äž»èŠã°ããŒãã«åžå Žãšã®ãå»è¬åãã¹ïŒå»è¬åã®ã£ãããã«å¯ŸåŠãããããåžå°çŸæ£ãææçã«é¢ããèŠå¶ã®ç¶ç¶çãªç·©åãæåŸ ããŠãããæ¥éã«é²ãé«éœ¢å瀟äŒãåœæ°å¥åº·ä¿éºå¶åºŠãå§è¿«ããäžã宿çãªè¬äŸ¡æ¹å®ãè¡ãããäžæ¹ãå¿ èŠäžå¯æ¬ ãªå»è¬åã®åœå çç£ã奚å±ãããã
ç±³åœã§ã®åãã¯ã€ã³ãã«ã圱é¿ãåãŒãå¯èœæ§ãé«ãããã®å»è¬ååžå Žã¯ãã©ã³ãæ¬¡ææ¿æš©ããæ©æµãåããå¯èœæ§ããããBIOSECUREæ³æ¡ã®è¡æ¹ã«æ³šç®ãéãŸã£ãŠããããšAPACãšã°ãŒã¯ãã£ãã»ãšãã£ã¿ãŒã®ã¢ã³ãžã¥ã»ã¬ã³ã°ã«ãã¯èšããçŸåšã®å¢ãã¯ã倧æè£œè¬äŒç€Ÿãã€ã³ãã®èœåã»ã³ã¿ãŒã«ã¢ãŠããœãŒã·ã³ã°ããŠããããšã瀺ããŠããŸããã€ã³ãã®GMPïŒå»è¬å補é 管çåã³å質管çã«é¢ããåºæºïŒèŠå¶ã®æ¹æ£ãäžå°äŒæ¥ã«ãé©çšãããäºå®ã§ãããé©åã§ããªãå€ãã®äŒæ¥ãæ·æ±°ãããå¯èœæ§ããããããããéµå®æéã®å»¶é·ã®åããããèšåºè©Šéšã®å é€ã¯æ°è¬ã®äžåžãå éãããå¯èœæ§ããããã€ãããŒã·ã§ã³ã®é¢ã§ã¯ã倧æã€ã³ãäŒæ¥ã®åªåã¯ãããŒããã©ãªãªã®ã®ã£ãããåããããã®ã€ã³ã©ã€ã»ã³ã¹ãšè³ç£ã®ææºã«ãã£ãŠããã¯ã¢ãããããã ããã
éåœã«ã¯ãµãã©ã€ãºã¯ã»ãšãã©ãªããäžççãªãã¬ã³ãã«æ²¿ã£ããã®ãšãªã£ãŠãããã·ãã¢ã»ãšãã£ã¿ãŒã®Jung Won Shinæ°ã¯ãéåœã®è£œè¬æ¥çã¯ãæäœè¬ç©è€åäœãæšçã¿ã³ãã¯è³ªåè§£ãè¥æºçïŒä»£è¬æ§çŸæ£ãšãã£ãæ°ããæ²»çæ³ã®ç ç©¶éçºãè³ç£ãããããã®åéã®äžççãªæé·ãåããŠãä»åŸãç©æ¥µçã«æš¡çŽ¢ããŠããã ãããšè¿°ã¹ãŠãããéåœã§ãAIãžã®é¢å¿ãæ¥å¢ããŠããããã®åéã§ã®æ¿åºã®æ°èšç»ãèæ¯ã«ãå»è¬åéçºã«ãããAIã®å¿çšãå¢å ãããšäºæ³ãããŠããããŸããç¹ã«çç©è£œå€ã现èã»éºäŒåæ²»çè¬ã®éçºã»è£œé åèšæ©é¢ïŒCDMOïŒæ¥çã¯ãäžççãªéèŠã®é«ãŸããèæ¯ã«ãä»åŸãæé·ãç¶ãããšäºæ³ãããã
æžéè¬
GLP-1ç©èº«è¬ã¯ãã¡ãã£ã¢å ±éã«ãããŠå€©ç§€ãã²ã£ããè¿ããããè¿ãå°æ¥ããã軜ããªããšã¯æããªãã§ã»ãããCitelineã®å§åйäŒç€ŸEvaluateã«ããã°ãè¥æºæ²»çè¬åžå Žã¯2030幎ãŸã§ã«1260åãã«èŠæš¡ã«ãªããšæšå®ãããŠããããã ã
è¥æºæ²»çè¬ãŒããããŠã³ããšãŠã§ãŽããŒã®ç«¶äºã¯ããšãŒãšãŒãã€ãšããã®ããã«äžé²äžéãç¹°ãè¿ããŠããããªãªãŒã®ãŒããããŠã³ãã¯ãå°ãªããšã1ã€ã®å䜵çãæã€è¥æºçãŸãã¯éäœéã®æ£è ã察象ãšããçŽæ¥æ¯èŒè©Šéšã§ãããã»ãã«ãã£ã¹ã¯ã®ãŠã§ãŽããŒãäžåã£ãã12æãããã»ãã«ãã£ã¹ã¯ã®ã«ã°ãªã»ã第IIIçžè©Šéšã®çµæã¯äºæ³ãäžåã£ããã«ã°ãªã»ãã¯è©Šéšæéäžã«äœéã®22.7ïŒ ãæžå°ãããããããããã瀟ã®å¹¹éšã¯25ïŒ ã®äœéæžå°ãæåŸ ããŠãããæè³å®¶ãæå€§27ïŒ ãæåŸ ããŠãããã·ãã©ã€ã³ç€Ÿã¯ã300以äžã®æ°è¬åè£ããã€ãã©ã€ã³ã«ãããä»åŸ5幎ã»ã©ã§åžå Žã«ç»å Žãããšäºæ³ããŠããã
In Vivoã«ããã°ãã¢ããªã³äœåè¬ã¯æ¬¡ã«åžå Žã«ç»å Žããäž»èŠãªã«ããŽãªãŒã«ãªããããããªããã¢ããªã³ã¯ã€ã³ã¹ãªã³ãšå ±åæ³ããããã«ã¢ã³ã§ãGLP-1ã«äŒŒãŠããïŒæºè ¹æãé·ãæããããã°ã«ã«ãŽã³ïŒè¡ç³å€ãäžæããããã«ã¢ã³ïŒãæå¶ãããGLP-1ãšã¯ç°ãªããã¢ããªã³ãæäžãããŠãã人ã¯ãŸã ç©ºè ¹æãæããåãæ°ãçµéšããå¯èœæ§ã¯äœããããããªãã
In Vivoèªã«ããã°ãæ¶ååšç³»ã®å¯äœçšãªãã«é£æ¬²ãæããããšããä»ã®ç ç©¶è ããèèãè žãçèãèèªçµç¹ãªã©ã®äž»èŠãªä»£è¬åšå®ã«ååšããæ«æ¢¢ã«ã³ãããã€ãïŒCB1ïŒå容äœãæšçãšããã«ã³ãããã€ãç³»ã忀èšããŠããããã®ã¢ãããŒãã¯ãGLP-1ã®ããäžã€ã®åŒ±ç¹ã§ããé€èèªäœéã®æžå°ã«å¯ŸåŠããå¯èœæ§ãããã
ä»ã®ã¢ãããŒãã¯ã代è¬ã«çŠç¹ãåœãŠãŠãããããã³ã³ããªã¢ã®ã¢ã³ã«ãããªã³ã°ã¯ãèèªãç³è³ªããšãã«ã®ãŒãéã¶ATPååã§ã¯ãªãç±ã«å€ããèªç¶ãªããã»ã¹ã§ããããŸããAMP掻æ§åãããã€ã³ãããŒãŒïŒAMPKïŒã®æŽ»æ§åãç ç©¶ãããŠãããAMPKã¯ç³è³ªãèèªã®ä»£è¬ã®ãããªãšãã«ã®ãŒç£ççµè·¯ãä¿é²ããèèªçæã®ãããªãšãã«ã®ãŒè²¯èµéçšãé»å®³ãããããã«ã飿¬²ãèèªä»£è¬ã®ç°åžžã«ãã£ãŠè¥æºãåŒãèµ·ãããè³ã®ãã«ã¢ã³å¶åŸ¡äžæ¢ã§ããèŠåºäžéšã®ççã«æ³šç®ããã¢ãããŒããããã
DCTãã«ã ããã¯ïŒ
ã³ãããŠã€ã«ã¹ã®å€§æµè¡æã«ããŒã¯ãè¿ãã忣åèšåºè©ŠéšïŒDCTïŒã¯ã2024幎ã«ã¯ã»ãšãã©ã¬ãŒããŒããæ¶ããããã«èŠãããããããAIã®å°é ã«ãããDCTãžã®é¢å¿ãåã³é«ãŸã£ãŠããããã ãäžè¿°ã®ããã«ãèšåºè©Šéšã«ããã倿§æ§ãšæ£è äžå¿äž»çŸ©ãæšé²ããç¶ç¶çãªåãçµã¿ã¯ã忣åã¢ãããŒããæ¯æããŠããã
9æãFDAã¯DCTã«é¢ããæçµã¬ã€ãã³ã¹ãçºè¡šããããã®ã¬ã€ãã³ã¹ã®ç®æšã®äžã€ã¯ãèšåºè©Šéšåå è ã®è² æ ã軜æžããããšã§ãããä»åŸãæ¥çã®åªå äºé ã§ããç¶ããã§ãããæ£è äžå¿äž»çŸ©ãåæ ããŠãããå®éãæ£è äžå¿ã®ã¢ãããŒãã¯ãDCTã®ãããªèšåºè©Šéšã®å®æœæ¹æ³ã«ãšã©ãŸãããå®éã®æ£è åéã«ãŸã§åãã§ãããã¹ãã³ãµãŒã¯ãåŸæ¥ã®ã¢ãããŒãã«ãšã©ãŸãããèšåºè©Šéšæ å ±ããã³ãã¥ããã£ããŒã¿ã«ã販ä¿è³æã«è³ããŸã§ãæ£è ã®å奜ãèæ ®ããã¢ãããŒããæš¡çŽ¢ããŠããã
COVIDã®æããå ãïŒ
Journal of Clinical Investigationèªã«æ²èŒãããããŒã¹ãŠã§ã¹ã¿ã³å»åŠéšã®ç ç©¶ã«ãããCOVID-19ææãšçéçž®ãšã®é¢é£ãæããã«ãªã£ããç§åŠè ãã¯ãCOVID-19ã®åå ã§ããSARS-CoV-2ãŠã€ã«ã¹ã®RNAããæããäœçšã®ãããŠããŒã¯ãªã¿ã€ãã®å ç«çްèã®çºçãèªçºããããšã芳å¯ããããã®çºèŠã¯çæ²»çã®æ°ããªã¢ãããŒããšããŠæåŸ ãããã
2024幎ãããã¯ãã©ãŒã«æ ãä»ãè£œè¬æ¥çã¯ãã®å ã®æ°ããªçŽäœæ²æã«åããªããã°ãªããªããæåããçµç¹ã¯ãå€åããè£œè¬æ¥çã®ç¶æ³ã«å¯Ÿå¿ãããããå¿ èŠã«å¿ããŠã®ã¢ãã·ããããæºåãæŽããã ããã
èè ã«ã€ããŠ
Darcy Grabenstein
Director of Content Strategy and Thought Leadership | Citeline
Darcy is the Director of Content Strategy and Thought Leadership for Citeline. A journalist by training, she has more than 30 years of experience in marketing, advertising, and public relations.


